COVID-19 UPDATE: We are open! Our team is working and offering consultations via phone, e-mail, and video conferencing.
(251) 299-0101

Zantac Cancer Lawsuits and Recalls Continue to Increase

In September 2019, the Food and Drug Administration (FDA) first alerted the public that Zantac and other ranitidine medications – commonly used to treat heartburn and acid reflux – could contain dangerous levels of a “probable human carcinogen.” Over the following months, the FDA issued dozens of voluntary recalls for both over-the-counter and prescription drugs containing ranitidine, as research continued to show the presence of carcinogenic N-nitrosodimethylamine (NDMA) in Zantac and similar drugs.

Now, an independent California-based testing lab called Emery Pharma has filed an official Citizen Petition with the FDA, asking them to suspend all sales of ranitidine on the basis that these drugs contain an essential defect. Upon reviewing their data, these lab researchers found that NDMA can accumulate in ranitidine products after heat exposure – and that it may only take 5 days for dangerously high levels of NDMA to develop.

According to Emery CEO Ron Najafi, the researchers were alarmed by their discovery, which suggests that the toxicity levels in ranitidine can increase even in relatively mild temperatures. As Najafi shared with Bloomberg, “I am worried that if [Zantac] just sits at home at room temperature, it could gradually generate NDMA.”

This result echoes an earlier finding from Valisure, an online pharmacy service that discovered high levels of NDMA in every lot they tested. According to Valisure’s tests, a single Zantac or ranitidine tablet may contain the same levels of NDMA as 30 packs of cigarettes.

Vigorous Representation in Zantac Cases

Millions of Americans use Zantac and ranitidine drugs for both short-term and long-term heartburn issues, and it’s estimated that doctors write over 15 million prescriptions for Zantac each year. As the lawsuits and recalls for Zantac continue to grow, it’s imperative that injury victims hold pharmaceutical companies accountable for failing to identify and prevent dangerous drug defects.

Our award-winning plaintiff attorneys at Cunningham Bounds have been representing injury victims for over 60 years, and we are currently accepting cases related to Zantac injuries. We’ve been twice named as one of the top 10 personal injury firms in America, and all 12 of our partners have been selected by Alabama Super Lawyers, the Best Lawyers in America, and are AV Rated by Martindale-Hubbell®. When you work with our attorneys, you can expect the highest level of ingenuity and care for your case – and that we will pursue justice on your behalf with unparalleled vigor.

Call (251) 299-0101 to discuss your Zantac case with our experienced team.

Categories: